The Antibody-Drug Conjugates (ADC) Market has emerged as one of the most promising areas in the field of oncology. ADCs are a class of targeted cancer therapies that combine monoclonal antibodies with cytotoxic drugs, offering highly selective and potent treatments for cancer patients. By linking a potent cytotoxic agent to an antibody that specifically targets cancer cells, ADCs deliver the drug directly to tumor sites, minimizing damage to healthy tissues and increasing the efficacy of the treatment.